Predictive Value of MHR, PLR Combined With NLRP1 for Severity and Long-Term Prognosis in Premature Coronary Artery Disease

IF 3.1 4区医学 Q3 IMMUNOLOGY

Immunity, Inflammation and Disease Pub Date : 2025-05-19 DOI:10.1002/iid3.70202

Mengyun Zhu, Jianying Shen, Weijing Liu, Hui Sun, Yawei Xu

{"title":"Predictive Value of MHR, PLR Combined With NLRP1 for Severity and Long-Term Prognosis in Premature Coronary Artery Disease","authors":"Mengyun Zhu, Jianying Shen, Weijing Liu, Hui Sun, Yawei Xu","doi":"10.1002/iid3.70202","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>To investigate the predictive value of platelet to lymphocyte ratio (PLR), monocyte to high-density lipoprotein ratio (MHR) combined with nucleotide binding oligomeric domain like receptor protein 1 (NLRP1) for the severity of premature coronary heart disease (PCHD) and its 2-year long-term prognosis.</p>\n </section>\n \n <section>\n \n <h3> Method</h3>\n \n <p>A total of 132 patients with PCHD examined in our hospital from February 2020 to January 2022 were retrospectively selected as the research objects. All patients who met the criteria were divided into mild group, moderate group, and severe group according to the severity of PCHD. The patients were followed up for 2 years. Patients were then divided into good prognosis group (without adverse cardiovascular events, <i>n</i> = 96) and poor prognosis group (with adverse cardiovascular events, <i>n</i> = 36). The predictive value was evaluated by ROC curve and multivariate logistic regression analysis.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Compared with the mild group, the levels of MHR, PLR, and NLRP1 in the moderate group and the severe group were significantly increased (<i>p</i> < 0.05). The levels of MHR, PLR, and NLRP1 in the poor prognosis group were higher than the good prognosis group (<i>p</i> < 0.05). The area under the curve (AUC) of MHR, PLR, and NLRP1 alone and in combination for predicting the 2-year long-term prognosis of patients was 0.787, 0.653, 0.869, and 0.926, respectively. Combined markers showed superior predictive accuracy (<i>p</i> < 0.05). After adjusting for confounding factors such as treatment, comorbidities, weight, gender, and smoking, MHR, PLR, and NLRP1 were independent risk factors for severe progression and poor prognosis of PCHD (<i>p</i> < 0.05).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>MHR, PLR, and NLRP1 were increased in patients with higher severity of PCHD and poor prognosis. The combined detection has certain clinical guiding value for PCHD. However, this study was a single-center retrospective study with a small sample size. Thus, the results need to be further verified.</p>\n </section>\n </div>","PeriodicalId":13289,"journal":{"name":"Immunity, Inflammation and Disease","volume":"13 5","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iid3.70202","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunity, Inflammation and Disease","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/iid3.70202","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

To investigate the predictive value of platelet to lymphocyte ratio (PLR), monocyte to high-density lipoprotein ratio (MHR) combined with nucleotide binding oligomeric domain like receptor protein 1 (NLRP1) for the severity of premature coronary heart disease (PCHD) and its 2-year long-term prognosis.

Method

A total of 132 patients with PCHD examined in our hospital from February 2020 to January 2022 were retrospectively selected as the research objects. All patients who met the criteria were divided into mild group, moderate group, and severe group according to the severity of PCHD. The patients were followed up for 2 years. Patients were then divided into good prognosis group (without adverse cardiovascular events, n = 96) and poor prognosis group (with adverse cardiovascular events, n = 36). The predictive value was evaluated by ROC curve and multivariate logistic regression analysis.

Results

Compared with the mild group, the levels of MHR, PLR, and NLRP1 in the moderate group and the severe group were significantly increased (p < 0.05). The levels of MHR, PLR, and NLRP1 in the poor prognosis group were higher than the good prognosis group (p < 0.05). The area under the curve (AUC) of MHR, PLR, and NLRP1 alone and in combination for predicting the 2-year long-term prognosis of patients was 0.787, 0.653, 0.869, and 0.926, respectively. Combined markers showed superior predictive accuracy (p < 0.05). After adjusting for confounding factors such as treatment, comorbidities, weight, gender, and smoking, MHR, PLR, and NLRP1 were independent risk factors for severe progression and poor prognosis of PCHD (p < 0.05).

Conclusion

MHR, PLR, and NLRP1 were increased in patients with higher severity of PCHD and poor prognosis. The combined detection has certain clinical guiding value for PCHD. However, this study was a single-center retrospective study with a small sample size. Thus, the results need to be further verified.

查看原文本刊更多论文

MHR、PLR联合NLRP1对早发性冠状动脉疾病严重程度和远期预后的预测价值

目的探讨血小板与淋巴细胞比值（PLR）、单核细胞与高密度脂蛋白比值（MHR）联合核苷酸结合寡聚结构域样受体蛋白1 （NLRP1）对早冠心病（PCHD）严重程度及其2年远期预后的预测价值。方法回顾性选择2020年2月至2022年1月在我院检查的132例PCHD患者作为研究对象。所有符合标准的患者根据PCHD的严重程度分为轻度组、中度组和重度组。随访2年。将患者分为预后良好组（无心血管不良事件，n = 96）和预后不良组（有心血管不良事件，n = 36）。采用ROC曲线和多因素logistic回归分析评价预测价值。结果与轻度组比较，中度组和重度组患者MHR、PLR、NLRP1水平均显著升高（p < 0.05）。预后不良组MHR、PLR、NLRP1水平均高于预后良好组（p < 0.05）。MHR、PLR、NLRP1单独及联合预测患者2年远期预后的曲线下面积（AUC）分别为0.787、0.653、0.869、0.926。联合标记具有更好的预测准确性（p < 0.05）。在调整治疗、合并症、体重、性别、吸烟等混杂因素后，MHR、PLR、NLRP1是PCHD严重进展和预后不良的独立危险因素（p < 0.05）。结论PCHD严重程度越高，预后越差，MHR、PLR、NLRP1水平越高。联合检测对PCHD有一定的临床指导价值。然而，本研究为单中心回顾性研究，样本量小。因此，研究结果还有待进一步验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunity, Inflammation and Disease Medicine-Immunology and Allergy

CiteScore

3.60

自引率

0.00%

发文量

146

审稿时长

8 weeks

期刊介绍： Immunity, Inflammation and Disease is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research across the broad field of immunology. Immunity, Inflammation and Disease gives rapid consideration to papers in all areas of clinical and basic research. The journal is indexed in Medline and the Science Citation Index Expanded (part of Web of Science), among others. It welcomes original work that enhances the understanding of immunology in areas including: • cellular and molecular immunology • clinical immunology • allergy • immunochemistry • immunogenetics • immune signalling • immune development • imaging • mathematical modelling • autoimmunity • transplantation immunology • cancer immunology